The European Union has approved ® (yew alcohol beam) for the treatment of platinum-sensitive endoskine cancer

Ovarian cancer is a type of cancer that begins in the ovaries.
ovarian cancer, the most common type is ovarian cortoma, which develops from ovarian skin tissue.
cancer is rare in young women, usually in post-menotinal women.
biopharmaceutical company Elevar Therapeutics announced today that its Apealea® (Yew alcohol beam) has been authorized by European regulators to be used in the European Economic Area in partnership with capratin for the treatment of adult patients with platinum-sensitive epitheliotic, primary peritiotic and fallopian tube cancers that have relapsed for the first time. alex Kim, chief executive of
Elevar Therapeutics, said: "We are pleased to announce a partnership with Inceptua to provide Apealea ® (yew alcohol beam) to ovarian cancer patients in Europe.
Apealea is the only non-Cremophor-based yew alcohol therapy approved in Europe for ovarian cancer, with higher doses of Apealea, shorter infusion time, and no mandatory pre-drug treatment than Cremophor-based yew alcohol."
。